Clinical trial / 1999
Intravenous GLP-1 infusions dose-dependently reduced food, calorie, and fluid intake in healthy men.
Sixteen healthy male volunteers received graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 in a double-blind, placebo-controlled setup. Graded GLP-1 infusions caused a dose-dependent reduction in food intake (maximal inhibition 35%, p<0.001 vs control), calorie intake (32% reduction, p<0.001), and fluid ingestion (18% reduction, p<0.01). At the highest dose, participants reported less hunger and early fullness prior to a meal (p<0.05), with no overt side effects observed.
- Study type
- Double-blind, placebo-controlled trial
- Who was studied
- 16 healthy male subjects
- What was measured
- Food intake, calorie intake, fluid ingestion, hunger, and satiety
THE PAPER
Glucagon-like peptide-1: a potent regulator of food intake in humans.
Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Gut, 1999.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.